NP_036423.4
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Related Accession #
Molecular Weight
197,745 Da
NCBI Official Full Name
separin
NCBI Official Synonym Full Names
extra spindle pole bodies like 1, separase
NCBI Official Synonym Symbols
NCBI Protein Information
separin
UniProt Protein Name
Separin
UniProt Synonym Protein Names
Caspase-like protein ESPL1; Extra spindle poles-like 1 protein; Separase
UniProt Synonym Gene Names
UniProt Entry Name
ESPL1_HUMAN
NCBI Summary for ESPL1
Stable cohesion between sister chromatids before anaphase and their timely separation during anaphase are critical for chromosome inheritance. In vertebrates, sister chromatid cohesion is released in 2 steps via distinct mechanisms. The first step involves phosphorylation of STAG1 (MIM 604358) or STAG2 (MIM 300826) in the cohesin complex. The second step involves cleavage of the cohesin subunit SCC1 (RAD21; MIM 606462) by ESPL1, or separase, which initiates the final separation of sister chromatids (Sun et al., 2009 [PubMed 19345191]).[supplied by OMIM, Nov 2010]
UniProt Comments for ESPL1
separase: a caspase-like protease, which plays a central role in the chromosome segregation by cleaving the SCC1/RAD21 subunit of the cohesin complex at the onset of anaphase. During most of the cell cycle, it is inactivated by different mechanisms. Regulated by at least two independent mechanisms. First, it is inactivated via its interaction with securin/PTTG1, which probably covers its active site. Second, phosphorylation inactivates it. It is completely phosphorylated during mitosis and dephosphorylated during anaphase. Two alternatively spliced isoforms have been described.
Protein type: EC 3.4.22.49; Protease
Chromosomal Location of Human Ortholog: 12q
Cellular Component: centrosome; cytoplasm; cytosol; nucleus
Molecular Function: cysteine-type endopeptidase activity; cysteine-type peptidase activity; protein binding
Biological Process: apoptosis; meiotic chromosome separation; mitotic sister chromatid segregation
Research Articles on ESPL1
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-ESPL1 antibody
Pathways associated with anti-ESPL1 antibody
Diseases associated with anti-ESPL1 antibody
Disease Name |
Pubmed Publications |
Breast Neoplasms Antibodies |
>8 publications with ESPL1 and Breast Neoplasms |
Neoplasms, Experimental Antibodies |
>6 publications with ESPL1 and Neoplasms, Experimental |
Cell Transformation, Neoplastic Antibodies |
>5 publications with ESPL1 and Cell Transformation, Neoplastic |
Disease Models, Animal Antibodies |
>3 publications with ESPL1 and Disease Models, Animal |
Infertility, Female Antibodies |
>2 publications with ESPL1 and Infertility, Female |
Neoplasm Invasiveness Antibodies |
>1 publications with ESPL1 and Neoplasm Invasiveness |
Lung Neoplasms Antibodies |
>1 publications with ESPL1 and Lung Neoplasms |
Chromosome Breakage Antibodies |
>1 publications with ESPL1 and Chromosome Breakage |
Infertility, Male Antibodies |
>1 publications with ESPL1 and Infertility, Male |
Carcinoma, Transitional Cell Antibodies |
>1 publications with ESPL1 and Carcinoma, Transitional Cell |
Organs/Tissues associated with anti-ESPL1 antibody
|